More on ATNM
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.89 |
|
|||
| Open | $0.90 | ||||
| 52 Wk High | $3.50 | ||||
| 52 Wk Low | $0.86 | ||||
| Day High | $0.93 | ||||
| Day Low | $0.89 | ||||
| P/E | N/A | ||||
| EPS | $-7.61 | ||||
| Volume | 56,468 | ||||
- Form 8-K Actinium Pharmaceuticals For: Jun 18
- Actinium presents ATNM-400 data at SNMMI showing activity in lung cancer
- Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
- Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
- Actinium Pharmaceuticals names Steffen Heeger as chief medical officer
- Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
- Actinium Pharmaceuticals presents CAR optimization data at SNMMI 2026
- Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
- Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
- Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
Entities mentioned with ATNM
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Show More...
